Human Technopole awarded FIS grant for precision immunotherapy research
The Giustacchini Group of the Genomics Research Centre of Human Technopole has been awarded a €1.66 million grant from the Fondo Italiano per la Scienza (FIS 2) to advance precision immunotherapy for haematological malignancies. The three-year project, titled “Tailoring Precision Immunotherapy to Haematological Malignancies”, aims to develop more effective cell-based therapies for blood cancers by integrating molecular, cellular and systems-level analyses.
Led by Alice Giustacchini, the project will investigate how blood cancers reshape the immune system and how these changes influence the effectiveness of immune cell therapies.
“By capturing the complex interplay between tumour, immune system and therapy, this project will allow us to design cellular treatments that are truly adapted to each disease’s biology.” said Alice Giustacchini.
The project will leverage the five Human Technopole’s National Facilities, enabling integrated analyses across molecular and cellular scales. In addition, the research will be carried out in close collaboration with University College London and Ospedale Pediatrico Bambino Gesù, strengthening international and clinical links.
By bringing together systems-level insight into immune–tumour interactions with translational cell therapy design, this work reflects Human Technopole’s commitment to advancing fundamental discovery with a clear impact on human health. The long-term ambition is to help shape a new generation of immunotherapies that are more precise, effective and tailored to patients’ biological diversity.
Share:
You could also like:
-
From RNA to proteins: AIRC supports Human Technopole’s new approaches to cancer research
Lorenzo Calviello and his group of the Human Technopole’s Research Centres for Genomics and Computational Biology have been awarded a five-year My First AIRC Grant by Fondazione AIRC per la Ricerca sul Cancro. The grant provides over €99,000 for 2026, for a total of €500,000, to support a project aimed at identifying cancer-specific proteins that could serve as new immunotherapy targets in colorectal cancer.
-
How sortilin senses thyroglobulin along its pathway to thyroid hormone release
Human Technopole researchers have identified the molecular mechanisms by which the membrane receptor sortilin binds thyroglobulin along its pathway to the release of thyroid hormones within the thyroid gland. The results of the research were published in Nature Communications and highlight that sortilin senses thyroglobulin via a short flexible “tag” which appears to be a common motif for the recognition of other partner proteins throughout our body.
-
AI4Life: A European Success for Artificial Intelligence in the Life Sciences
The AI4Life project, co-led by Florian Jug (Computational Biology Research Centre at Human Technopole) and Anna Kreshuk (EMBL), received the highest possible score in the European Commission’s final review, recognising its scientific impact and the quality of its achievements in applying artificial intelligence to biological image analysis.
-
Highlights from the 2nd Conference “Future Trends in Translational Medicine”
Turning scientific discoveries into real-world therapies was the focus of the second international conference “Future Trends in Translational Medicine – From Molecules to Therapies,” held at the Complesso Universitario di San Giovanni a Teduccio in Naples on 30 -31 October 2025.
-
Happy Holidays and a Bright New Year from Human Technopole
As 2025 comes to a close, we look back at a year shaped by connection, discovery and growth. At Human Technopole, progress happens when perspectives meet, between disciplines, technologies and people. Our holiday card captures this idea visually: what looks like a festive forest is actually a colon under the microscope, a structure that changes depending on how you look at it, reminding us that science often begins with a shift in perspective.